ACHV:NSD-Achieve Life Sciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.07

Change

+0.14 (+1.57)%

Market Cap

USD 0.03B

Volume

0.04M

Average Target Price

USD 21.00 (+131.53%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.60 (+0.74%)

USD56.30B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+2.21 (+0.44%)

USD54.00B 20.76 16.02
MRNA Moderna, Inc

+10.62 (+10.78%)

USD39.00B N/A N/A
SGEN Seagen Inc

+0.82 (+0.50%)

USD29.47B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

-0.18 (-0.15%)

USD26.94B 28.36 26.40
RPRX Royalty Pharma plc

+1.39 (+3.51%)

USD24.75B 23.05 9.48
BNTX BioNTech SE

+3.09 (+3.03%)

USD24.53B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.98 (+3.11%)

USD23.81B N/A N/A
GMAB Genmab A/S

+0.68 (+1.93%)

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACHV

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.43% 40% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.43% 40% F 30% F
Trailing 12 Months  
Capital Gain -50.71% 13% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.71% 13% F 6% F
Trailing 5 Years  
Capital Gain -98.49% 8% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.49% 8% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -9.03% N/A N/A 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.03% N/A N/A 19% F
Risk Return Profile  
Volatility (Standard Deviation) 58.19% N/A N/A 18% F
Risk Adjusted Return -15.52% N/A N/A 26% F
Market Capitalization 0.03B 10% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.80 65% D 88% B+
Price/Book Ratio 1.28 92% A- 70% C-
Price / Cash Flow Ratio -2.12 26% F 65% D
EV/EBITDA 0.36 56% F 93% A
Management Effectiveness  
Return on Equity -78.07% 40% F 15% F
Return on Invested Capital -97.65% 26% F 9% F
Return on Assets -42.31% 23% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.81 41% F 25% F
Short Percent 15.95% 16% F 14% F
Beta 1.40 56% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.